{"id":14375,"date":"2023-08-31T16:12:00","date_gmt":"2023-08-31T08:12:00","guid":{"rendered":"https:\/\/flcube.com\/?p=14375"},"modified":"2024-11-23T16:17:56","modified_gmt":"2024-11-23T08:17:56","slug":"junshi-biosciences-reports-h1-2023-revenue-dip-amid-commercial-success-and-rd-focus","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=14375","title":{"rendered":"Junshi Biosciences Reports H1 2023 Revenue Dip Amid Commercial Success and R&D Focus"},"content":{"rendered":"\n

China\u2019s Junshi Biosciences (HKG: 1877<\/a>; SHA: 688180<\/a>) has released its financial report for the first half of 2023, recording RMB 670 million (USD 91.9 million) in revenues, a 29.21% year-on-year (YOY) decrease, primarily due to decreased licensing income. Despite this, commercialized products generated RMB 625 million (USD 85.8 million), marking a 103% YOY increase. Research and development expenditure for the period was RMB 949 million (USD 130.2 million), down 10.7% YOY.<\/p>\n\n\n\n

Strong Performance of Commercialized Products<\/strong>
During the period, Junshi’s programmed death-1 (PD-1) inhibitor Tuoyi (toripalimab) generated RMB 447 million (USD 61.3 million), up 50% YOY. As of the reporting date, Tuoyi has been sold in over 4,000 medical institutions and 2,000 professional and private drugstores. Additionally, three supplementary New Drug Applications (sNDAs) for Tuoyi are under review for various cancer treatments.<\/p>\n\n\n\n

COVID-19 Therapy Mindewei’s Market Performance<\/strong>
COVID-19 therapy Mindewei (deuremidevir) obtained conditional approval in January for the treatment of mild to moderate COVID-19 adult cases and was temporarily included in the National Reimbursement Drug List (NRDL). After a price adjustment in April, the drug was re-listed in the NRDL and generated RMB 110 million (USD 15 million) during the period, accessible in more than 2,200 hospitals.<\/p>\n\n\n\n

Biosimilar Version of Humira and Patent Portfolio<\/strong>
Partner Mabwell’s biosimilar version of AbbVie\u2019s Humira (adalimumab) brought in RMB 68 million (USD 9.3 million) during the period, with online procurement completed in 25 provinces. In 2023, the drug was entered into 67 formularies covering 172 hospitals and 955 pharmacies accumulatively. As of the reporting date, Junshi Bio owns 126 patents, including 98 overseas patents, and has nearly 30 programs under clinical development.-Fineline Info & Tech<\/a><\/p>\n\n\n\n

<\/p>\n","protected":false},"excerpt":{"rendered":"

China\u2019s Junshi Biosciences (HKG: 1877; SHA: 688180) has released its financial report for the first…<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":false,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7],"tags":[27,899,296,900],"class_list":["post-14375","post","type-post","status-publish","format-standard","hentry","category-company","tag-finanical-reports","tag-hkg-1877","tag-junshi-biosciences","tag-sha-688180"],"yoast_head":"\nJunshi Biosciences Reports H1 2023 Revenue Dip Amid Commercial Success and R&D Focus - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"China\u2019s Junshi Biosciences (HKG: 1877; SHA: 688180) has released its financial report for the first half of 2023, recording RMB 670 million (USD 91.9 million) in revenues, a 29.21% year-on-year (YOY) decrease, primarily due to decreased licensing income. Despite this, commercialized products generated RMB 625 million (USD 85.8 million), marking a 103% YOY increase. Research and development expenditure for the period was RMB 949 million (USD 130.2 million), down 10.7% YOY.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=14375\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Junshi Biosciences Reports H1 2023 Revenue Dip Amid Commercial Success and R&D Focus\" \/>\n<meta property=\"og:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=14375\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2023-08-31T08:12:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-11-23T08:17:56+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=14375#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=14375\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Junshi Biosciences Reports H1 2023 Revenue Dip Amid Commercial Success and R&D Focus\",\"datePublished\":\"2023-08-31T08:12:00+00:00\",\"dateModified\":\"2024-11-23T08:17:56+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=14375\"},\"wordCount\":261,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Finanical Reports\",\"HKG: 1877\",\"Junshi Biosciences\",\"SHA: 688180\"],\"articleSection\":[\"Company\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=14375#respond\"]}],\"copyrightYear\":\"2023\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=14375\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=14375\",\"name\":\"Junshi Biosciences Reports H1 2023 Revenue Dip Amid Commercial Success and R&D Focus - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2023-08-31T08:12:00+00:00\",\"dateModified\":\"2024-11-23T08:17:56+00:00\",\"description\":\"China\u2019s Junshi Biosciences (HKG: 1877; SHA: 688180) has released its financial report for the first half of 2023, recording RMB 670 million (USD 91.9 million) in revenues, a 29.21% year-on-year (YOY) decrease, primarily due to decreased licensing income. Despite this, commercialized products generated RMB 625 million (USD 85.8 million), marking a 103% YOY increase. Research and development expenditure for the period was RMB 949 million (USD 130.2 million), down 10.7% YOY.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=14375#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=14375\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=14375#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Junshi Biosciences Reports H1 2023 Revenue Dip Amid Commercial Success and R&D Focus\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Junshi Biosciences Reports H1 2023 Revenue Dip Amid Commercial Success and R&D Focus - Insight, China's Pharmaceutical Industry","description":"China\u2019s Junshi Biosciences (HKG: 1877; SHA: 688180) has released its financial report for the first half of 2023, recording RMB 670 million (USD 91.9 million) in revenues, a 29.21% year-on-year (YOY) decrease, primarily due to decreased licensing income. Despite this, commercialized products generated RMB 625 million (USD 85.8 million), marking a 103% YOY increase. Research and development expenditure for the period was RMB 949 million (USD 130.2 million), down 10.7% YOY.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=14375","og_locale":"en_US","og_type":"article","og_title":"Junshi Biosciences Reports H1 2023 Revenue Dip Amid Commercial Success and R&D Focus","og_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","og_url":"https:\/\/flcube.com\/?p=14375","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2023-08-31T08:12:00+00:00","article_modified_time":"2024-11-23T08:17:56+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=14375#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=14375"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Junshi Biosciences Reports H1 2023 Revenue Dip Amid Commercial Success and R&D Focus","datePublished":"2023-08-31T08:12:00+00:00","dateModified":"2024-11-23T08:17:56+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=14375"},"wordCount":261,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Finanical Reports","HKG: 1877","Junshi Biosciences","SHA: 688180"],"articleSection":["Company"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=14375#respond"]}],"copyrightYear":"2023","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=14375","url":"https:\/\/flcube.com\/?p=14375","name":"Junshi Biosciences Reports H1 2023 Revenue Dip Amid Commercial Success and R&D Focus - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2023-08-31T08:12:00+00:00","dateModified":"2024-11-23T08:17:56+00:00","description":"China\u2019s Junshi Biosciences (HKG: 1877; SHA: 688180) has released its financial report for the first half of 2023, recording RMB 670 million (USD 91.9 million) in revenues, a 29.21% year-on-year (YOY) decrease, primarily due to decreased licensing income. Despite this, commercialized products generated RMB 625 million (USD 85.8 million), marking a 103% YOY increase. Research and development expenditure for the period was RMB 949 million (USD 130.2 million), down 10.7% YOY.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=14375#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=14375"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=14375#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Junshi Biosciences Reports H1 2023 Revenue Dip Amid Commercial Success and R&D Focus"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/14375","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=14375"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/14375\/revisions"}],"predecessor-version":[{"id":14376,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/14375\/revisions\/14376"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=14375"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=14375"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=14375"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}